ShanXi C&Y Pharmaceutical Group Co.,LTD. (SHE:300254)

Market Cap	2.71B
Revenue (ttm)	818.49M
Net Income (ttm)	9.07M
Shares Out	256.17M
EPS (ttm)	0.04
PE Ratio	280.36
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,986,060
Average Volume	7,919,206
Open	10.43
Previous Close	10.41
Day's Range	10.41 - 10.62
52-Week Range	7.44 - 14.23
Beta	0.16
RSI	41.77
Earnings Date	Oct 24, 2025

About SHE:300254

ShanXi C&Y Pharmaceutical Group Co.,LTD. engages in the research, development, production, and sale of medicine and health food products. It provides anti-infective drugs, anti-allergic drugs, respiratory drugs, urinary system drugs, kidney disease drugs, children's drugs, cardiovascular and cerebrovascular drugs, anti-depressants, medicines, pharmaceutical raw materials, and intermediates, etc. The company’s product portfolio includes Fosfomycin tromethamine powder, Ebastine tablets, Tamsulosin hydrochloride sustained release capsules, Cinacal...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2005
• Employees: 1,196
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300254

Financial Performance

In 2024, SHE:300254's revenue was 846.61 million, an increase of 5.92% compared to the previous year's 799.31 million. Earnings were 42.19 million, an increase of 67.45%.